Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has 1 licensing announcement in this dataset, dated 2025-09-03.
- Country / operating region
- China
- Ticker
- 02315.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- biocytogen.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| RenMice antibody-conjugated LNP programs | 查無 | 查無 | 查無 | 2025-09-03 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| RenMice antibody-conjugated LNP programs | 查無 | — | 查無 | 查無 | 2025-09-03 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2025-09-03 | Merck KGaA, Darmstadt, Germany | RenMice antibody-conjugated LNP programs | 查無 | 查無 | 查無 | 查無 | Evaluation and exclusive option to acquire selected antibody rights. |
| Counterparty | Territory | Royalties |
|---|---|---|
| Merck KGaA, Darmstadt, Germany | 查無 | Fees and royalties on sales and sublicenses; rates undisclosed. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無